• Has over 31 years of experience in R&D, BD and management in the biopharmaceutical industry
• Served as the vice president of CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Limited, and the vice president of Qilu Pharmaceutical Co., Ltd.
• Served as the Asia head of external innovation for endocrine and cardiovascular system at the Lilly China R&D Center of Eli Lilly and Company
• Served as director of external collaborative drug discovery projects at Merck Sharp & Dohme Corp. and director of medicinal chemistry at Metabasis Therapeutics, Inc.
• Participated in the R&D of various drugs and drug candidates for clinical use, including a first generation and a second generation FBPase inhibitor for the treatment of type II diabetes